Improving the immunogenicity of E. coli FimH via multivalent display on I53-50 nanoparticles - Summary - MDSpire

Enhancing the Immunogenic Response of E. coli FimH through Multivalent Presentation on I53-50 Nanoparticles

  • By

  • Rebecca S. Cole

  • Natalie C. Silmon de Monerri

  • Jacqueline Lypowy

  • Christopher Ponce

  • Cara Kobylarz

  • Lily Liu

  • Zein Kasbo

  • Elizabeth Kepl

  • Tara Ciolino

  • Art Illenberger

  • Leslie Gallardo

  • Annalena Laporte

  • Danielle Baranova

  • Rashmi Ravichandran

  • Laurent O. Chorro

  • Robert G.K. Donald

  • Raphael Simon

  • Neil P. King

  • July 21, 2026

Share

Objective:

To investigate the immunogenicity of FimH antigens displayed on I53-50 nanoparticles as potential vaccine candidates against urinary tract infections caused by uropathogenic E. coli, focusing on the elicitation of antibody responses.

Approach:
  • Nanoparticle Immunogen Development: FimH antigens were displayed on I53-50 nanoparticles to create multivalent immunogens aimed at eliciting robust antibody responses through enhanced immune activation.
  • Comparative Analysis: The immunogenicity of FimH lectin domain (FimHLD) and a stabilized antigen (FimH-DSG) was compared when presented on nanoparticles versus in soluble form, assessing antibody response levels and receptor-blocking activity.
Key Findings:
  • Nanoparticle immunogens elicited robust receptor-blocking antibodies in both mice and non-human primates.
  • Both FimHLD and FimH-DSG displayed on I53-50 nanoparticles induced similar receptor-blocking activity as a higher dose of monomeric FimH-DSG with potent adjuvants.
  • The use of I53-50 nanoparticles improved the immunogenicity of FimH antigens compared to soluble forms.
Interpretation:

The study provides preclinical evidence supporting the use of I53-50 nanoparticles for enhancing the immunogenic response to bacterial antigens, specifically FimH, which is a candidate for UTI vaccines.

Limitations:
  • The study primarily focuses on preclinical models; further clinical trials are needed to validate findings in humans.
  • The long-term efficacy and safety of the nanoparticle-based vaccines have yet to be established.
Conclusion:

The findings suggest that I53-50 nanoparticle display significantly enhances the immunogenicity of FimH antigens, paving the way for future vaccine development against urinary tract infections.

Original Source(s)

Improving the immunogenicity of E. coli FimH via multivalent display on I53-50 nanoparticles

  • by Rebecca S. Cole, Natalie C. Silmon de Monerri, Jacqueline Lypowy, Christopher Ponce, Cara Kobylarz, Lily Liu, Zein Kasbo, Elizabeth Kepl, Tara Ciolino, Art Illenberger, Leslie Gallardo, Annalena Laporte, Danielle Baranova, Rashmi Ravichandran, Laurent O. Chorro, Robert G.K. Donald, Raphael Simon, Neil P. King

  • July 21, 2026

Related Content

Mechanisms of Epstein-Barr virus-associated autoimmunity: a comparative overview

How Pandemics Have Reshaped the Respiratory Virus Data Landscape in Europe: Scoping Review

Development and internal validation of a frailty risk stratification model for older patients with spinal tuberculosis